Cerity Partners’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
Other funds holding IMDX
AIC
Cerity Partners's IMDX Position: Q3 2026 in Review
Cerity Partners opened a new position in Insight Molecular Diagnostics (IMDX) in Q3 2026: 11,947 shares worth $42.9K. The stake represents ﹤0.01% of the portfolio and ranks #3348 among its holdings.
44 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.
- Cerity Partners held 11,947 shares of Insight Molecular Diagnostics worth $42.9K as of Q3 2026.
- Insight Molecular Diagnostics was a new Cerity Partners position in Q3 2026.
- Insight Molecular Diagnostics made up ﹤0.01% of Cerity Partners's portfolio in Q3 2026, its #3348 holding.
- 44 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.
Based on Cerity Partners's 13F filing for Q3 2026, filed 13 Nov 2026.